Candel Therapeutics Inc (CADL) - Total Liabilities
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has total liabilities worth $63.89 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Candel Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Candel Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Candel Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Candel Therapeutics Inc's balance sheet.
Candel Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Candel Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Xinneng Photovoltaic Technology Co Ltd
SHG:603105
|
China | CN¥2.37 Billion |
|
Bright Minds Biosciences Inc
NASDAQ:DRUG
|
USA | $2.55 Million |
|
Baida Group Co Ltd
SHG:600865
|
China | CN¥159.43 Million |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
USA | $4.06 Billion |
|
Shandong Luyang Share Co Ltd
SHE:002088
|
China | CN¥632.73 Million |
|
Chengdu M&S Electronics Technology Co Ltd
SHG:688311
|
China | CN¥587.29 Million |
|
Zhejiang Netsun Co Ltd
SHE:002095
|
China | CN¥411.65 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Candel Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CADL net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Candel Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Candel Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Candel Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $73.27 Million | +80.75% |
| 2024-12-31 | $40.54 Million | +42.46% |
| 2023-12-31 | $28.46 Million | -7.63% |
| 2022-12-31 | $30.80 Million | +22.89% |
| 2021-12-31 | $25.07 Million | -59.47% |
| 2020-12-31 | $61.84 Million | +14.66% |
| 2019-12-31 | $53.94 Million | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more